



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

Re: Xigris
Docket Nos. 02E-0099, 02E-0184, and 03E-0255

The Honorable Jon Dudas
Acting Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Acting Director Dudas:

This is in regard to the patent term extension applications for U.S. Patent Nos. 4,775,624; 5,681,932; and 5,270,040 filed by Eli Lilly & Company under 35 U.S.C. § 156. The patents claims Xigris (drotrecogin alfa), BLA 125029/0.

In the November 25, 2003, issue of the Federal Register (68 Fed. Reg. 66112), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before May 24, 2004, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Brian P. Barrett
Eli Lilly & Company
Patent Division, BPB
Lilly Corporate Center
Indianapolis, IN 46285

03E-0255

LET 3